Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics is exploring the use of its Accum technology to enhance the efficacy and prolong the half-life of GLP-1 agonists in treating obesity and related conditions such as type 2 diabetes. The company aims to address challenges like tolerability, injection frequency, and patient compliance, amidst a rapidly growing market for GLP-1 receptor agonists, projected to be worth over US$ 125 billion by 2033.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
